title: Prognostic factors and treatment outcome in childhood Hodgkin disease.
abstract: BACKGROUND
  The goals of this study included: (1) Identification of factors prognostic for event-free survival (EFS) and overall survival (OS), and (2) Definition of risk groups for risk adapted therapy in children with Hodgkin disease (HD).
  
  
  METHODS
  From 1991 to 2003, 69 children with newly diagnosed, untreated biopsy-proven stage I-IV HD were treated with chemotherapy (CT) and low-dose involved field radiotherapy (LD-IFRT). The relationship of pretreatment factors to EFS and OS was analyzed by univariate and multivariate analysis.
  
  
  RESULTS
  The 5-year EFS and OS for all patients were 90.77% and 96.22%, respectively with a median follow-up of 73 months (3-137 months). Male to female ratio was 3:1 and 21 children (32.3%) were less than 7 years of age. Mixed cellularity was the predominant histologic subtype (38.5%). Factors associated with inferior EFS by univariate analysis were extranodal disease, hemoglobin level <11 g/dl, number of involved lymph node regions and stage. By multivariate analysis only stage IV disease was significant.
  
  
  CONCLUSIONS
  Our study confirms that excellent results are achievable with combined modality therapy in childhood HD. In order to use risk-adapted therapy in children with HD, clinical prognostic factors should be validated with large, multicentered prospective clinical studies.
authors: Department of Pediatrics, Professor of Pediatric Oncology, Chief of Division, Gazi University Faculty of Medicine, Beşevler/Ankara, Turkey.
authors: Aynur
authors: A
authors: Oguz
authors: Ceyda
authors: C
authors: Karadeniz
authors: F Visal
authors: FV
authors: Okur
authors: E Caglar
authors: EC
authors: Citak
authors: F Guçlu
authors: FG
authors: Pinarli
authors: Huseyin
authors: H
authors: Bora
authors: Nalan
authors: N
authors: Akyurek
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D011379:Prognosis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins